PHARMACOTHERAPEUTICAL CONSIDERATIONS IN THE TREATMENT AND MANAGEMENT OF NEONATAL HYPERAMMONAEMIA
CLAUDIA JURCA 1,2#, MARIUS BEMBEA 2#, ANAMARIA PALLAG 1#, MARIANA MUREȘAN 1#, ARIANA SZILAGYI 1,2#, ANDREEA BALMOȘ 1#, OVIDIU POP 1,2#, ALEXANDRU JURCA 1#*, LUCIANA DOBJANSCHI 1#
1.University of Oradea, Faculty of Medicine and Pharmacy
2.“Dr. Gavril Curteanu” Municipal Clinical Hospital of Oradea
*corresponding author: [email protected]
#All authors contributed equally to this article.
Download Full Article PDF
Amoniemia is a normal biochemical condition, the result of nitrogen compounds metabolism. The normal level of free ammonia in human plasma is usually less than 35 μmol/L. Increased ammonia levels over 35 μmol/L is named hyperammonaemia (HA), a metabolic condition that becomes clinically evident by disrupting the neurotransmitters systems caused by neuronal damages. Neonatal hyperammonaemia is rare, being caused in most of the cases by the inborn error of the metabolism due to the urea cycle enzymes deficiency. They are pathological conditions with vital concern, whose recognition, early diagnosis and treatment are essential for the survival and the quality of life. The main treatment is medication together with a dietary approach.